Sign up Australia
Proactive Investors - Run By Investors For Investors

AusCann Group Holdings harvesting first crop in Chile

Joint venture company DayaCann is currently harvesting in Chile.
AusCann Group Holdings harvesting first crop in Chile
The stock has quadrupled since listing in February now trading at $0.825

AusCann Group Holdings (ASX:AC8) is in the process of harvesting its first medical cannabis crop located in Chile.

The crop was planted by the DayaCann joint venture, of which AusCann holds 50:50 with Fundacion Daya.

The large open greenhouse grown plants include various strains that have been selected for specific medical usage.

An estimated 300 kilograms of dried cannabis product from the harvest will be sent to a certified manufacturing facility for processing into medicinal cannabis formulations.

Elaine Darby, managing director, commented: “We’re delighted with the harvest of our first crop with our partner Fundacion Daya and we’re confident we have selected the strongest and most appropriate strains for effective medicine formulations and further cultivation in the next harvest.”


Next steps and local market opportunity

Of the strains harvested, four have been selected as superior strains that have been clonally selected for future crops.

Pending successful clinical trials in Chile, these formulations will be registered through the Chilean National Institute of Public Health and made available for sale to Chilean patients and export markets.

South America represents a burgeoning region for medicinal cannabis with Argentina recently giving legislative approval to legalise the use of cannabis oil and other cannabis derivatives for medicinal purposes.

The Health Ministry in Argentina have also established a medical cannabis research program to provide access for patients.

DayaCann is optimally positioned in Argentina’s neighbouring country Chile to become a supplier of clinically validated medical cannabis products to Argentinian patients.

AusCann is also looking at leveraging this knowledge gained from Chile into the Australian market.


Background

Medical cannabis company, AusCann, commenced trading on the ASX in February after it raised the maximum $5 million under its prospectus offering.

AusCann intends to establish a growing facility in Australia to eventually supply Australian patients with Australian grown and manufactured medicines.

However, until domestic approvals are received, AusCann’s medicinal products will be imported from its globally recognised partners.

View full AC8 profile View Profile

AusCann Group Holdings Ltd Timeline

Related Articles

Vial of pills
Fri
Cosmos is a modern company, but the trade routes it relies on are ancient
lab
March 15 2018
Amryt's lead drug candidate, AP101, is a potential treatment for epidermolysis bullosa, a rare genetic skin disorder for which there is currently no approved treatment
researcher filling a vial
April 24 2018
2018 is shaping up to be a crucial year for the company's drug pipeline

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use